| Autor: |
Chen J; Department of Internal Medicine, Division of Allergy, Michigan Nanotechnology, Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, Michigan, USA., Cao Z; Department of Internal Medicine, Division of Allergy, Michigan Nanotechnology, Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, Michigan, USA., Cannon J; Department of Internal Medicine, Division of Allergy, Michigan Nanotechnology, Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, Michigan, USA., Fan Y; Department of Internal Medicine, Division of Allergy, Michigan Nanotechnology, Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, Michigan, USA., Baker JR Jr; Department of Internal Medicine, Division of Allergy, Michigan Nanotechnology, Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, Michigan, USA., Wang SH; Department of Internal Medicine, Division of Allergy, Michigan Nanotechnology, Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, Michigan, USA. |
| Abstrakt: |
Wound infections with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are particularly difficult to treat and present a great challenge to clinicians. Nanoemulsions (NE) are novel oil-in-water emulsions formulated from soybean oil, water, solvent, and surfactants such as benzalkonium chloride (BZK). An optimal ratio of those components produces nanometer-sized particles with the positive-charged surfactant at their oil-water interface. We sought to investigate antimicrobial NE as a novel treatment to address wounds co-infected by MRSA and VRE. Swine split-thickness skin wounds were first infected with MRSA and/or VRE, then treated with the nanoemulsion formulation (X-1735) or placebo controls. Bacterial viability after treatment were determined by nutrient agar plates for total, MRSA-specific, and VRE-specific loads. In addition, inflammation indexes were scored by histopathology. When VRE infected wounds were treated with X-1735, they contained 10 3 lower VRE CFU counts across a 2-week period compared with placebo. Once co-infected MRSA and VRE split-thickness wounds were successfully established, topical treatment of co-infected wounds with X-1735 resulted in a reduction of bacteria by 2 to 3 logs (compared with placebo) at 3- and 14-day postinfection time points. Importantly, X-1735 was effective in significantly alleviating multilevel inflammation in the treated wounds. X-1735 is a new antimicrobial that is safe to apply to open wounds and effectively kills MRSA and VRE. It appears to also reduce inflammation in these co-infected wounds. The data suggest that this approach offers promise as an antimicrobial for open wounds with MRSA and VRE co-infection. IMPORTANCE Infections, specifically polymicrobial, can cause serious consequences when it comes to wound treatment. Prolonged treatment with antibiotics can lead to an increased risk of bacterial resistance; co-infections can complicate treatment options even further. Our research proposes a novel nanoemulsion treatment for two of the most common antibiotic resistant bacteria: methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant enterococci (VRE). This optimized topical treatment formulation not only significantly reduces inflammation and infection in MRSA or VRE infected wounds, but also in MRSA and VRE co-infected wounds as well. The work aims to provide an alternative treatment approach for multidrug-resistant organisms and decrease dependence on systemic treatments. |
